Here's what the filings actually say: Lilly spent 2025 turning a single blockbuster idea into a patent estate. The grants aren't one invention restated — they're a methodical broadening of claims across the incretin class.
Incretins are the gut hormones, GIP and GLP-1, that govern blood sugar and appetite. Lilly's lead drug acts on both. The 2025 record shows the company patenting around that dual mechanism repeatedly. Grant US12252524B2 covers GIP/GLP-1 co-agonist compounds, with claims reaching into formulation and dosing.
Two more grants extend the same idea. US12295987B2 covers a method of using a GIP/GLP1 co-agonist for diabetes, and US12365716B2 covers incretin analogs and their uses. Same inventors recur across them — this is one program filing in waves.
Why file so many overlapping claims? Because a franchise this valuable can't rest on a single patent with a single expiry. By covering the compound, the method of use, the analogs, and the formulation separately, a company forces any challenger to clear every live claim — and staggers the dates so the protected core keeps moving forward.
The crosswalk worth keeping: when you see a wave of grants to one company on one mechanism in one year, you're watching a moat being dug, not a new discovery. Lilly's 2025 incretin grants are a defensive roadmap for the drug class it leads.
The honest caveat is that a thick estate slows challengers but doesn't stop the underlying science. Competitors are filing on the same dual- and triple-agonist territory. The 2025 grants tell you Lilly intends to defend the franchise aggressively — they don't tell you the competition won't eventually route around it.